Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Rises By 556.9%

GT Biopharma, Inc. (NASDAQ:GTBP) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 90,000 shares, an increase of 556.9% from the December 31st total of 13,700 shares. Approximately 4.6% of the shares of the company are short sold. Based on an average daily trading volume, of 365,300 shares, the short-interest ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GTBP. Roth Capital upgraded GT Biopharma to a “strong-buy” rating in a research report on Monday, December 2nd. Roth Mkm began coverage on GT Biopharma in a report on Monday, December 2nd. They set a “buy” rating and a $11.00 target price for the company.

GT Biopharma Stock Up 2.9 %

NASDAQ:GTBP traded up $0.06 during trading hours on Tuesday, hitting $2.10. The stock had a trading volume of 59,287 shares, compared to its average volume of 282,899. The company has a 50 day simple moving average of $2.68 and a two-hundred day simple moving average of $2.53. GT Biopharma has a one year low of $1.72 and a one year high of $10.66.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.